These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 17502783

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
    Peng PW, Huang MC, Tsai CJ, Pan CH, Chen CC, Chiu CC.
    J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reversal of symptomatic hyperprolactinemia by aripiprazole.
    Wahl R, Ostroff R.
    Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
    [No Abstract] [Full Text] [Related]

  • 7. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
    Lai YC, Chiou CC, Chen CH, Huang MC.
    J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hyperprolactinaemia on depot risperidone treated with aripiprazole.
    Anandarajan T, Tibrewal P, Dhillon R, Bastiampillai T.
    Aust N Z J Psychiatry; 2012 Aug; 46(8):792-3. PubMed ID: 22528973
    [No Abstract] [Full Text] [Related]

  • 10. Clinical guidelines: Dosing and switching strategies for long-acting risperidone.
    Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS.
    J Clin Psychiatry; 2003 Aug; 64 Suppl 16():41-6. PubMed ID: 14680418
    [No Abstract] [Full Text] [Related]

  • 11. Leukopenia during therapy with risperidone long-acting injectable: two case reports.
    Uzun S, Kozumplik O, Jakovljević M, Folnegović-Smalc V.
    J Clin Psychopharmacol; 2008 Dec; 28(6):713-4. PubMed ID: 19011449
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
    Anta L, Llaudó J, Ayani I, Martínez J, Litman RE, Gutierro I.
    Int Clin Psychopharmacol; 2018 Mar; 33(2):79-87. PubMed ID: 29112001
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
    Ishitobi M, Kosaka H, Shukunami K, Murata T, Wada Y.
    J Clin Psychopharmacol; 2011 Jun; 31(3):400-1; author reply 401. PubMed ID: 21532377
    [No Abstract] [Full Text] [Related]

  • 17. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 18. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.